ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION

GHENT, Belgium, 31 July 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 24,967 common shares have been issued by the Company in exchange for €199,086.96 as the result of the exercise of warrants by some employees and consultants of the Company.

As a result of this transaction, Ablynx now has 54,512,424 shares outstanding.

The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights currently is 2,894,795 which equals the total number of voting rights that may result from the exercise of these warrants. Currently 1,000 convertible bonds are outstanding entitling the holders thereof to 7,733,952 shares of the Company in the aggregate, upon conversion of such convertible bonds.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Merck Serono, Novartis and Taisho Pharmaceutical. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:   [phone]
m: [phone]
e:  [e-mail]

Marieke Vermeersch
Associate Director Investor Relations
t:   [phone]
m: [phone]
e:  [e-mail]
Follow us on Twitter @AblynxABLX

Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t:   [phone]
e:  [e-mail]

Jim Rusagara
Brussels office
t:   [phone]
e:  [e-mail]

pdf format of the press release

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#1942629